Prokineticin 1 mediates fetal-maternal dialogue regulating endometrial leukemia inhibitory factor

Jemma Evans, Rob D Catalano, Pamela Brown, Rob Sherwin, Hilary O D Critchley, Asgerally T Fazleabas, Henry N Jabbour, Jemma Evans, Rob D Catalano, Pamela Brown, Rob Sherwin, Hilary O D Critchley, Asgerally T Fazleabas, Henry N Jabbour

Abstract

Implantation requires communication between a receptive endometrium and a healthy blastocyst. This maternal-embryonic crosstalk involves local mediators within the uterine microenvironment. We demonstrate that a secreted protein, prokineticin 1 (PROK1), is expressed in the receptive endometrium and during early pregnancy. PROK1 induces expression of leukemia inhibitory factor (LIF) in endometrial epithelial cells and first trimester decidua via a Gq-Ca(2+)-cSrc-mitogen-activated protein kinase kinase-mediated pathway. We show that human embryonic chorionic gonadotropin (hCG) induces sequential mRNA expression of PROK1 and LIF in an in vivo baboon model, in human endometrial epithelial cells, and in first-trimester decidua. We have used micro RNA constructs targeted to PROK1 to demonstrate that hCG-mediated LIF expression in the endometrium is dependent on prior induction of PROK1. Dual immunohistochemical analysis colocalized expression of the luteinizing hormone/chorionic gonadotropin receptor, PROK1, PROKR1, and LIF to the glandular epithelial cells of the first trimester decidual tissue. PROK1 enhances adhesion of trophoblast cells to fibronectin and laminin matrices, which are mediated predominantly via LIF induction. These data describe a novel signaling pathway mediating maternal-embryonic crosstalk, in which embryonic hCG via endometrial PROK1 may play a pivotal role in enhancing receptivity and maintaining early pregnancy.

Figures

Figure 1.
Figure 1.
PROK1 induces LIF mRNA and protein expression. LIF mRNA (A) and protein (B) expression in WT and PROKR1 Ishikawa cells after treatment with 40 nM PROK1. LIF mRNA and protein expression peaked at 6 and 12 h, respectively, in PROKR1 Ishikawa cells. No elevation in LIF mRNA expression was observed in WT Ishikawa cells. Expression of LIF mRNA (C) and protein (D) was measured after treatment with 40 nM PROK1 (lane 1) in the absence or presence of YM254890 (Gq inhibitor, lane 2), BAPTA-AM (calcium inhibitor, lane 3), PKC inhibitor (Ro-318220, lane 4), cSrc inhibitor (PP2, lane 5), EGFR inhibitor (AG1478, lane 6), or MEK inhibitor (PD98059, lane 7). PROK1-induced LIF mRNA and protein expression was significantly inhibited in the presence of these inhibitors. Bars represent means ± se of at least 3 independent experiments. *P < 0.05. ns, not significant; −, absence of agent; +, presence of agent.
Figure 2.
Figure 2.
hCG mediates expression of LIF via induction of PROK1. Expression of PROK1 in baboon endometrium was elevated after treatment with 1.25 IU of hCG/h for 5 d (A). Treatment of Ishikawa PROKR1 cells with 1 IU of hCG results in increased expression of PROK1 which peaks at 6 h (B). Similarly, treatment of Ishikawa PROKR1 cells with 1 IU of hCG results in increased expression of LIF, which peaks at 16 h (C). LIF mRNA expression in response to treatment with hCG is inhibited when PROKR1 Ishikawa cells are treated with 1 IU of hCG in the presence of cycloheximide (protein synthesis inhibitor) (D). PROKR1 Ishikawa cells were transiently transfected with miRNA constructs targeting PROK1 or scrambled sequences and subsequently treated with 1 IU of hCG. hCG-mediated PROK1 (E) and LIF (F) expression were significantly inhibited by PROK1 miRNA constructs. Bars represent means ± se of at least 3 independent experiments. *P < 0.05.
Figure 3.
Figure 3.
Temporal expression and colocalization of signaling components. LH/CG receptor (A), PROK1 (B) and LIF (C) mRNA in human endometrium across the menstrual cycle and first trimester decidua. P, proliferative; ES, early secretory; MS, mid secretory, w7, w8, w9, w10, and w11 represent weeks of gestation (n=sample size from each stage of the cycle and early pregnancy). Immunofluorescent histochemical analysis of the LH/CG receptor (red panel) and PROK1 (green panel) show colocalization to the glandular epithelial cells of first trimester decidua (yellow panel, merge) (D). PROKR1 (green panel) and LIF (red panel) colocalize to glandular epithelial cells and a subset of stromal cells of first trimester decidua (yellow panel, merge) (E). Data are means ± se. *P < 0.05; ***P < 0.001.
Figure 4.
Figure 4.
hCG mediates expression of LIF via induction of PROK1 in first trimester decidua. Treatment of first trimester decidua with 1 IU of hCG results in increased expression of PROK1 that peaks at 6 h (A). Similarly, treatment of first trimester decidua with 1 IU of hCG results in increased expression of LIF that peaks at 14 h (B). LIF mRNA expression in response to treatment with hCG is inhibited when first trimester decidua is treated with 1 IU of hCG for 14 h in the presence cycloheximide (protein synthesis inhibitor) (C). First trimester decidua tissue was infected with lentivirus encoding miRNA constructs targeting PROK1 or a scrambled sequence. Infected tissue was subjected to stimulation with 1 IU of hCG and subsequently analyzed for LIF mRNA expression. hCG-mediated LIF expression was significantly inhibited by PROK1 miRNA constructs compared with scrambled sequences (D). Bars represent means ± se of at least 3 independent experiments. *P < 0.05.
Figure 5.
Figure 5.
PROK1 induces LIF expression in first trimester decidua. Treatment of first trimester decidua with 40 nM PROK1 induced LIF mRNA (A) and protein (B) expression that peaked at 6 and 12 h, respectively. Expression of LIF mRNA in first trimester decidua was measured after treatment with 40 nM PROK1 (lane 1) in the absence or presence of YM254890 (Gq inhibitor, lane 2), BAPTA-AM (calcium inhibitor, lane 3), PKC inhibitor (Ro-318220, lane 4), cSrc inhibitor (PP2, lane 5), EGFR inhibitor (AG1478, lane 6), or MEK inhibitor (PD98059, lane 7) (C). PROK1-induced LIF mRNA expression was significantly inhibited in the presence of these inhibitors. Bars represent means ± se of at least 3 independent experiments. *P < 0.05.
Figure 6.
Figure 6.
PROK1 via LIF increases adhesion of trophoblast cells to fibronectin and laminin. Treatment of JEG-3 trophoblast cells with LIF increased adhesion to fibronectin (A, lane 6) and laminin (B, lane 6) compared with vehicle-treated cells (A, B; lane 5). Treatment of JEG-3 cells with conditioned medium collected from PROKR1 Ishikawa cells treated with 40 nM PROK1 for 24 h (PROK1 CM) also increased adhesion to fibronectin (A, lane 2) and laminin (B, lane 2) compared with conditioned medium collected from PROKR1 Ishikawa cells treated with vehicle for 24 h (vehicle CM; A, B; lane 1). This PROK1-mediated adhesion was abolished when LIF was immunoneutralized from the PROK1-conditioned medium (A, B; lane 4). Bars represent means ± se of at least 3 independent experiments. *P < 0.05. Ab, immunoneutralization.

References

    1. Psychoyos A. Hormonal control of ovoimplantation. Vitam Horm. 1973;31:201–256.
    1. Tabibzadeh S. Molecular control of the implantation window. Hum Reprod Update. 1998;4:465–471.
    1. Goto S, Kadowaki T, Hashimoto H, Kokeguchi S, Shiotani M. Stimulation of endometrium embryo transfer: injection of embryo culture supernatant into the uterine cavity before blastocyst transfer can improve implantation and pregnancy rates. Fertil Steril. 2007;88:1339–1343.
    1. Filicori M, Fazleabas A T, Huhtaniemi I, Licht P, Rao C H V, Tesarik J, Zygmunt M. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril. 2005;84:275–284.
    1. De Ziegler D, Mattenberger C, Schwarz C, Ibecheole V, Fournet N, Bianchi-Demicheli F. New tools for optimizing endometrial receptivity in controlled ovarian hyperstimulation: aromatase inhibitors and LH/(mini)hCG. Ann N Y Acad Sci. 2004;1034:262–277.
    1. Battersby S, Critchley H O, Morgan K, Millar R P, Jabbour H N. Expression and regulation of the prokineticins (endocrine gland-derived vascular endothelial growth factor and Bv8) and their receptors in the human endometrium across the menstrual cycle. J Clin Endocrinol Metab. 2004;89:2463–2469.
    1. Evans J, Catalano R D, Morgan K, Critchley H O, Millar R P, Jabbour H N. Prokineticin 1 signaling and gene regulation in early human pregnancy. Endocrinology. 2008;149:2877–2887.
    1. Hoffmann P, Feige J J, Alfaidy N. Expression and oxygen regulation of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 and its receptors in human placenta during early pregnancy. Endocrinology. 2006;147:1675–1684.
    1. Stewart C L, Kaspar P, Brunet L J, Bhatt H, Gadi I, Kontgen F, Abbondanzo S J. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature. 1992;359:76–79.
    1. Bhatt H, Brunet L J, Stewart C L. Uterine expression of leukaemia inhibitory factor coincides with the onset of blastocyst implantation. Proc Natl Acad Sci U S A. 1991;88:11408–11412.
    1. Arici A, Engin O, Attar E, Olive D L. Modulation of leukemia inhibitory factor gene expression and protein biosynthesis in human endometrium. J Clin Endocrinol Metab. 1995;80:1908–1915.
    1. Vogiagis D, Marsh M M, Fry R C, Salamonsen L A. Leukaemia inhibitory factor in human endometrium throughout the menstrual cycle. J Endocrinol. 1996;148:95–102.
    1. Perrier d'Hauterive S, Charlet-Renard C, Berndt S, Dubois M, Munaut C, Goffin F, Hagelstein M T, Noel A, Hazout A, Foidart J M, Geenen V. Human chorionic gonadotropin and growth factors at the embryonic-endometrial interface control leukaemia inhibitory factor (LIF) and interleukin 6 (IL-6) secretion by human endometrial epithelium. Hum Reprod. 2004;19:2633–2643.
    1. Sherwin J R, Sharkey A M, Cameo P, Mavrogianis P M, Catalano R D, Edassery S, Fazleabas A T. Identification of novel genes regulated by chorionic gonadotropin in baboon endometrium during the window of implantation. Endocrinology. 2007;148:618–626.
    1. Licht P, Russu V, Lehmeyer S, Wildt L. Molecular aspects of direct LH/hCG effects on human endometrium—lessons from intrauterine microdialysis in the human female in vivo. Reprod Biol. 2001;1:10–19.
    1. Tapia A, Salamonsen L A, Manuelpillai U, Dimitriadis E. Leukemia inhibitory factor promotes human first trimester extravillous trophoblast adhesion to extracellular matrix and secretion of tissue inhibitor of metalloproteinases-1. Hum Reprod. 2008;23:1724–1732.
    1. Norwitz E R, Schust D J, Fisher S J. Implantation and the survival of early pregnancy. N Engl J Med. 2001;345:1400–1408.
    1. Srisuparp S, Strakovam Z, Fazleabas A T. The role of chorionic gonadotropin (CG) in blastocyst implantation. Arch Med Res. 2001;32:627–634.
    1. Licht P, Fluhr H, Neuwinger J, Wallwiener D, Wildt L. Is human chorionic gonadotropin directly involved in the regulation of human implantation? Mol Cell Endocrinol. 2007;269:85–92.
    1. Fouladi-Nashta A A, Jones C J, Nijjar N, Mohamet L, Smith A, Chambers I, Kimber S J. Characterization of the uterine phenotype during the peri-implantation period for LIF-null, MF1 strain mice. Dev Biol. 2005;281:1–21.
    1. Steck T, Giess R, Suetterlin M W, Bolland M, Wiest S, Poehls U G, Dietl J. Leukaemia inhibitory factor (LIF) gene mutations in women with unexplained infertility and recurrent failure of implantation after IVF and embryo transfer. Eur J Obstet Gynecol Reprod Biol. 2004;112:69–73.
    1. Hambartsoumian E. Endometrial leukaemia inhibitory factor (LIF) as a possible cause of unexplained infertility and multiple failures of implantation. Am J Reprod Immunol. 1998;39:137–143.
    1. Carlson C D, Bai Y, Jonakait G M, Hart R P. Interleukin-1β increases leukaemia inhibitory factor mRNA levels through transient stimulation of transcription rate. Glia. 1996;18:141–151.
    1. Elias J A, Zheng T, Whiting N L, Marcovici A, Trow T K. Cytokine-cytokine synergy and protein kinase C in the regulation of lung fibroblast leukemia inhibitory factor. Am J Physiol. 1994;266:426–435.
    1. Fan Z, Bau B, Yang H, Aigner T. IL-1β induction of IL-6 and LIF in normal articular human chondrocytes involves the ERK, p38 and NFκB signalling pathways. Cytokine. 2004;28:17–24.
    1. Bamberger A M, Erdmann I, Jenatschke S, Bamberger C M, Schulte H M. Regulation of the human leukaemia inhibitory factor (LIF) promoter in HEC-1B endometrial adenocarcinoma cells. Mol Hum Reprod. 1997;3:789–793.
    1. Sawai K, Matsuzaki N, Okada T, Shimoya K, Koyama M, Azuma C, Saji F, Murata Y. Human decidual cell biosynthesis of leukemia inhibitory factor: regulation by decidual cytokines and steroid hormones. Biol Reprod. 1997;56:1274–1280.
    1. Ren S G, Melmed S, Braunstein G D. Decidual leukemia inhibitory factor production and action on human chorionic gonadotropin secretion at different stages of gestation in vitro. Early Pregnancy. 1997;3:102–108.
    1. Red-Horse K, Zhou Y, Genbacev O, Prakobphol A, Foulk R, McMaster M, Fisher S J. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J Clin Invest. 2004;114:744–754.
    1. Lunghi L, Ferretti M E, Merci S, Bondi C, Vesce F. Control of human trophoblast function. Reprod Biol Endocrinol. 2007;5:6.
    1. Sawai K, Matsuzaki N, Kameda T, Hashimoto K, Okada T, Shimoya K, Nobunaga T, Taga T, Kishimoto T, Saji F. Leukemia inhibitory factor produced at the fetomaternal interface stimulates chorionic gonadotropin production: its possible implication during pregnancy, including implantation period. J Clin Endocrinol Metab. 1995;80:1449–1456.
    1. Nachtigall M J, Kliman H J, Feinberg R F, Olive D L, Engin O, Arici A. The effect of leukemia inhibitory factor (LIF) on trophoblast differentiation: a potential role in human implantation. J Clin Endocrinol Metab. 1996;81:801–806.
    1. Bischof P, Haenggeli L, Campana A. Effect of leukemia inhibitory factor on human cytotrophoblast differentiation along the invasive pathway. Am J Reprod Immunol. 1995;34:225–230.
    1. Ferenczy A. Ultrastructure of the normal menstrual cycle: a review. Microsc Res Tech. 1993;25:91–105.
    1. Fernandez P L, Merino M J, Nogales F F, Charonis A S, Stetler-Stevenson W, Liotta L. Immunohistochemical profile of basement membrane proteins and 72 kilodalton type IV collagenase in the implantation placental site: an integrated view. Lab Invest. 1992;66:572–579.
    1. Faber M, Wewer U M, Berthelsen J G, Liotta L A, Albrechtsen R. Laminin production by human endometrial stromal cells relates to the cyclic and pathologic state of the endometrium. Am J Pathol. 1986;124:384–391.
    1. Dockery P, Khalid J, Sarani S A, Bulut H E, Warren M A, Li T C, Cooke I D. Changes in basement membrane thickness in the human endometrium during the luteal phase of the menstrual cycle. Hum Reprod Update. 1998;4:486–495.
    1. Delage G, Moreau J F, Taupin J L, Freitas S, Hambartsoumian E, Olivennes F, Fanchin R, Letur-Konirsch H, Frydman R, Chaouat G. In-vitro endometrial secretion of human interleukin for DA cells/leukaemia inhibitory factor by explant cultures from fertile and infertile women. Hum Reprod. 1995;10:2483–2488.
    1. Lédée-Bataille N, Laprée-Delage G, Taupin J L, Dubanchet S, Frydman R, Chaouat G. Concentration of leukaemia inhibitory factor (LIF) in uterine flushing fluid is highly predictive of embryo implantation. Hum Reprod. 2002;17:213–218.
    1. Mikolajczyk M, Skrzypczak J, Szymanowski K, Wirstlein P. The assessment of LIF in uterine flushing—a possible new diagnostic tool in states of impaired fertility. Reprod Biol. 2003;3:259–270.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel